 |
2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant melanoma stages IIB to IV |
| USA Market Approval | USA |
| USA Designation Date | 2015-06-23 00:00:00 |
| Sponsor | Rgenix, Inc.;310 East 67th St., Suite 1-12;New York, New York, 10065 |
